Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783442 · ClinicalTrials.gov registry record · Phase 3
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
A Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene.
- Completed
- Registry status
- Phase 3
- Development phase
- 649
- Enrollment target
- 20
- Study locations
NCT03783442 is a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC) that has completed, run by BeiGene. The registered enrollment target is 649 participants, above the 489-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT03783442, a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 649 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Oxaliplatin
- DRUG Paclitaxel
- DRUG Fluorouracil (5-FU)
Study Locations (20)
Other
- Institut Jules Bordet - Anderlecht
- Az Sint Jan Brugge - Bruges
- Grand Hopital de Charleroi Site Notre Dame - Charleroi
- UZ GENT - Ghent
- University Hospitals Leuven - Leuven
- Chc Montlegia - Liège
Beijing Municipality
- Beijing Friendship Hospital, Capital Medical University - Beijing
- The Fifth Medical Center of Chinese Pla General Hospital - Beijing
- Beijing Cancer Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
Anhui
- Anhui Provincial Hospital - Hefei
- Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital - Hefei
- The Second Hospital of Anhui Medical University - Hefei
Fujian
- The First Affiliated Hospital of Fujian Medical University - Fuzhou
- Fujian Cancer Hospital - Fuzhou
- Quanzhou First Affliated Hospital of Fujian Medical University - Quanzhou
Connecticut
- Smilow Cancer Hospital At Yale - New Haven
Texas
- Renovatio Clinical - The Woodlands
New South Wales
- Coffs Harbour Base Hospital - Coffs Harbour
Victoria
- St Vincents Hospital Melbourne - Fitzroy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783442
The ClinicalTrials.gov registry entry for NCT03783442 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 649 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 489-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target (33% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma (ESCC) appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT03783442 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Beijing Municipality, Anhui.
Frequently Asked Questions
What is clinical trial NCT03783442 about?
NCT03783442 is a clinical study titled "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma". The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
What is the current status of trial NCT03783442?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 649 participants. The study started on 2018-12-11. Estimated completion is 2024-08-22.
What conditions does trial NCT03783442 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma (ESCC).
What interventions are being tested in trial NCT03783442?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Oxaliplatin (DRUG), Paclitaxel (DRUG), Fluorouracil (5-FU) (DRUG).
Who is sponsoring clinical trial NCT03783442?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03783442 being conducted?
This trial has 20 study locations across Connecticut, Texas, New South Wales, Victoria, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma (ESCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
COMPLETED · Phase 3
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
-
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.